| Drug ID: | Drug137 |
|---|---|
| Drug Name: | ABX464 |
| CID: | 49846599 |
| DrugBank ID: | DB14828 |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | NULL |
| Other Approved: | NULL |
| Identifier: | NCT04023396, , NCT05507203, , NCT05177835, , NCT05507216, , NCT03093259, , NCT03368118, , NCT05535946, , NCT03760003 |
| Molecular Formula: | C16H10ClF3N2O |
| Molecular Weight: | 338.71 g/mol |
| Isomeric SMILES: | C1=CC2=C(C(=C1)Cl)N=C(C=C2)NC3=CC=C(C=C3)OC(F)(F)F |
| Synonyms: | ABX-464; obefazimod; ABX464; 8-chloro-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine; Obefazimod [USAN]; 8-Chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine; OBEFAZIMOD [INN]; Abx 464; UNII-26RU378B9V; Obefazimod (USAN) |
| Phase 0: | 0 |
| Phase 1: | 0 |
| Phase 2: | 0 |
| Phase 3: | 0 |
| Phase 4: | 0 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT05507203 | ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 | PHASE3 | RECRUITING | Abivax S.A. | Ulcerative Colitis | DRUG: ABX464|DRUG: Placebo | Details |
| NCT05177835 | Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis | PHASE2 | ACTIVE_NOT_RECRUITING | Abivax S.A. | Ulcerative Colitis | DRUG: ABX464 | Details |
| NCT05507216 | ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 | PHASE3 | RECRUITING | Abivax S.A. | Ulcerative Colitis | DRUG: ABX464|DRUG: Placebo | Details |
| NCT03093259 | ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis | PHASE2 | COMPLETED | Abivax S.A. | Ulcerative Colitis | DRUG: ABX464|DRUG: Placebo oral capsule | Details |
| NCT03368118 | Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis | PHASE2 | COMPLETED | Abivax S.A. | Ulcerative Colitis | DRUG: ABX464 | Details |
| NCT03760003 | Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis | PHASE2 | COMPLETED | Abivax S.A. | Ulcerative Colitis | DRUG: ABX464 25mg|DRUG: ABX464 50mg|DRUG: ABX464 … | Details |
| NCT05535946 | ABTECT - Maintenance | PHASE3 | RECRUITING | Abivax S.A. | Ulcerative Colitis | DRUG: ABX464|DRUG: Placebo | Details |
| NCT04023396 | Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis | PHASE2 | UNKNOWN | Abivax S.A. | Ulcerative Colitis | DRUG: ABX464 | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
ABX464 (Obefazimod) Upregulates miR-124 to Reduce Proinflammatory Markers in In…
PMID: 36573890
Year: 2023
Relationship Type:
Treatment
Score: 9.5
Advanced therapies have transformed the treatment of inflammatory bowel disease; however, many patients fail to respond, highlighting the need for th…
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase …
PMID: 36075249
Year: 2022
Relationship Type:
Treatment
Score: 9.5
BACKGROUND: ABX464 (obefazimod) is a small molecule that selectively upregulates miR-124 in immune cells. We aimed to assess ABX464 as a treatment fo…
Specific and selective induction of miR-124 in immune cells by the quinoline AB…
PMID: 33387693
Year: 2021
Relationship Type:
Treatment
Score: 6.5
Inflammatory diseases are believed to develop as a result of dysregulated inflammatory responses to environmental factors on susceptible genetic back…
Obefazimod in patients with moderate-to-severely active ulcerative colitis: eff…
PMID: 40417999
Year: 2025
Relationship Type:
Treatment
Score: 5.5
BACKGROUND AND AIMS: Obefazimod is an oral small molecule that selectively enhances the expression of a single micro-RNA (miRNA), miR-124. Obefazimod…